Case study · Pharmaceuticals & biotech

AI across biologics and cell-therapy production at BMS Devens

Production based on living cells brings high scientific complexity and process variability.

Manufacturer
Bristol Myers Squibb
Use cases
1
Evidence
Independently assessed
Year
2026

Independently assessed  This result was assessed or published by a party other than the manufacturer or its vendor (a World Economic Forum Lighthouse assessment, a government or institute report, or a peer-reviewed paper).

The challenge

Production based on living cells brings high scientific complexity and process variability.

The approach

The site merged biopharma science with AI and digital strategies to create more than 30 new use cases.

Reported improvements

Percent change as reported by the source; hover for the exact wording

New product introduction time↓ 42%
Volume↑ 40%
Emissions↓ 40%

1 use case in this implementation

  1. Process & yield optimization

    More than 30 AI and digital use cases applied across biologics and cell-therapy manufacturing and new product introduction.

    • a 42% reduction in New Product Introduction (NPI) time
    • a volume increase of over 40%
    • a cut in emissions of more than 40%

Outcomes as reported by the source. We do not adjust, combine or extrapolate reported figures.

Related case studies

Put AI to work

Find the AI opportunities hiding in your plant.

Genvo, our implementation partner, works with manufacturers to pick the right first project, connect the systems you already run and put AI agents and tools into daily use, with people approving what goes out.

Assessments and consultations are provided by Genvo. How our partnership works.